Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT03121053

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03121053
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03121053. Randomized; no masking; primary purpose prevention. Start 2016-10 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
Acronym
PANTER
Condition
Aortic Valve Disease
Condition
Contrast Induced Nephropathy
Intervention (Drug)
sodium bicarbonate
Intervention (Drug)
hypotone saline
Lead sponsor
St. Antonius Hospital (class: other)

Record details

Record id
cardio:ct-nct03121053
Content hash
c432891d3c4fd9b40581fd44ac3330d059d3e0978a068e6f8681d61b5a30bfc5